SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025
Exploring the natural history of bone mineral density in Duchenne muscular dystrophy: a systematic literature review.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study.Journal of cachexia, sarcopenia and muscle · 2026Trial
- Total body and appendicular lean mass by dual-energy X-ray absorptiometry are highly associated with muscle function and bone mineral density in Becker muscular dystrophy.Journal of neuromuscular diseases · 2026Article
- Effects of intermittent corticosteroids on scoliosis, bone density, and vertebral fractures in duchenne muscular dystrophy.Journal of neuromuscular diseases · 2026Article
- The burden of bone disease in Duchenne muscular dystrophy: age-specific prevalence of osteoporosis and low bone density.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Vertebral fractures and muscle function in glucocorticoid-treated individuals with Duchenne muscular dystrophy: a cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Risk factors for abnormal bone mineral density in Duchenne muscular dystrophy and the association of regular rehabilitation with bone health.Frontiers in pediatrics · 2026Article
- Taohong Siwu Decoction Regulates MSC-Mediated H-Type Angiogenesis to Accelerate Bone Fracture Healing Through VHL/HIF-1α Ubiquitination.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn Duchenne muscular dystrophy (DMD) osteoporosis and fragility fractures present significant comorbidities, resulting from progressive myopathy reduced weight-bearing and osteotoxic effects of prolonged glucocorticoid (GC) use. This systematic literature review (SLR) assessed the natural course of bone mineral density (BMD) in individuals with DMD and the factors associated with its natural progression.
methodsA systematic literature review was conducted to evaluate BMD in individuals with DMD. Searches were performed in PubMed® and Embase® for peer-reviewed articles published between 2000 and 2023, focusing on DMD patients aged 5-15 years receiving GC treatment. Statistical analyses employed an initial correlation analyses followed by generalized linear mixed models (GLMMs) to investigate relationships between bone health biomarkers and clinical factors.
resultsStrong associations were observed between lumbar spine (LS) BMD Z-scores, age and GC treatment duration. LS areal BMD (aBMD) Z-scores declined with age (-0.25 SDS/year, p < 0.001, n = 1527) and with longer GC use (-0.24 SDS/year, p < 0.001, n = 817). Total body less head (TBLH) and lateral distal femur (LDF) BMD Z-scores also decreased with age at a rate of -0.26 SDS/year and - 0.41 SDS/year, respectively. The percentage of individuals with fractures increased by 21% (p < 0.01, n = 1066) for every 1-SDS decrease in LS aBMD Z-score. Reductions in LS aBMD Z-scores significantly accelerated after 11 years of age, with older versus younger individuals experiencing a faster decline.
conclusionUnderstanding the natural history of BMD and disease progression relating to bone fragility will help to support clinical trial design to assess and improve bone strength in DMD. To our knowledge, this is the first SLR investigating BMD Z-score trajectories in individuals with DMD receiving GCs and highlights associations between age and GC treatment duration with declining LS aBMD, TBLH, and LDF Z-scores.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.